Truist Financial Corp Purchases Shares of 21,406 Roivant Sciences Ltd. $ROIV

Truist Financial Corp purchased a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 21,406 shares of the company’s stock, valued at approximately $465,000.

A number of other hedge funds also recently bought and sold shares of ROIV. UBS Group AG lifted its stake in Roivant Sciences by 570.0% during the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after buying an additional 15,645,836 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in Roivant Sciences by 11,507.5% during the fourth quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company’s stock valued at $150,535,000 after buying an additional 6,877,348 shares in the last quarter. Perceptive Advisors LLC purchased a new stake in Roivant Sciences during the second quarter valued at about $37,546,000. Vanguard Group Inc. lifted its stake in Roivant Sciences by 8.4% during the fourth quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock valued at $912,681,000 after buying an additional 3,254,113 shares in the last quarter. Finally, Marshall Wace LLP lifted its stake in Roivant Sciences by 316.5% during the third quarter. Marshall Wace LLP now owns 3,978,001 shares of the company’s stock valued at $60,187,000 after buying an additional 3,022,851 shares in the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Roivant Sciences

In related news, CAO Jennifer Humes sold 13,538 shares of the stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $28.37, for a total value of $384,073.06. Following the transaction, the chief accounting officer owned 84,191 shares in the company, valued at approximately $2,388,498.67. This represents a 13.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Eric Venker sold 200,000 shares of the stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average price of $29.59, for a total value of $5,918,000.00. Following the completion of the transaction, the chief executive officer owned 1,647,546 shares in the company, valued at $48,750,886.14. This represents a 10.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 3,745,173 shares of company stock valued at $103,639,917 in the last ninety days. 10.80% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a research note on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Roivant Sciences in a research note on Friday, May 8th. Piper Sandler upped their target price on Roivant Sciences from $22.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 16th. Sanford C. Bernstein began coverage on Roivant Sciences in a report on Friday, March 20th. They issued an “outperform” rating and a $35.00 target price on the stock. Finally, Citigroup upped their target price on Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $30.55.

Roivant Sciences Price Performance

Shares of ROIV opened at $28.21 on Wednesday. The company has a market capitalization of $20.19 billion, a price-to-earnings ratio of -24.11 and a beta of 1.14. Roivant Sciences Ltd. has a fifty-two week low of $10.59 and a fifty-two week high of $30.33. The business’s 50-day moving average is $28.38 and its 200-day moving average is $24.85.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.